BiotechTube

Esomeprazole IV + Omeprazole IV

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Hemorrhage

Conditions

Gastrointestinal Hemorrhage

Trial Timeline

Aug 1, 2006 → Oct 1, 2007

NCT ID
NCT00402259

About Esomeprazole IV + Omeprazole IV

Esomeprazole IV + Omeprazole IV is a phase 3 stage product being developed by AstraZeneca for Gastrointestinal Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT00402259. Target conditions include Gastrointestinal Hemorrhage.

What happened to similar drugs?

6 of 20 similar drugs in Gastrointestinal Hemorrhage were approved

Approved (6) Terminated (4) Active (10)
🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
❌Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
🔄Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00402259Phase 3Completed

Competing Products

20 competing products in Gastrointestinal Hemorrhage

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
39
Patritumab deruxtecanDaiichi SankyoPhase 1/2
39
DS-6157aDaiichi SankyoPhase 1
21
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
35
Naldemedine + PlaceboShionogiPhase 2
27
GemcitabineEli LillyPhase 1/2
32
OlaratumabEli LillyPhase 2
27
pemetrexed + cisplatinEli LillyPhase 2
35
cetuximabEli LillyPhase 2
35
BBI503Sumitomo PharmaPhase 2
27
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
35
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
32
FamitinibJiangsu Hengrui MedicinePhase 2
31
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
44
EsomeprazoleAstraZenecaPhase 3
40
AZD2171AstraZenecaPhase 2
35
EsomeprazoleAstraZenecaPhase 3
40